ICN Licenses Drug to Treat Hepatitis B
- Share via
A Times Staff Writer
ICN Pharmaceuticals Inc. in Costa Mesa said it has licensed a compound for treating the liver disease hepatitis B from Metabasis Therapeutics of San Diego. Terms of the licensing deal were not disclosed.
ICN’s leading product is ribavirin, which is used in combination with a Schering-Plough Corp. drug to treat hepatitis C.
ICN shares rose 26 cents to $27.10 on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
